Silver-russell Syndrome
Silver-Russell syndrome is a congenital growth disorder presenting in infancy and early childhood with intrauterine and postnatal growth restriction, relative macrocephaly, a triangular face, body asymmetry, and feeding difficulties, most commonly caused by hypomethylation at chromosome 11p15 or maternal uniparental disomy of chromosome 7.
| Exam domain | One-glance essentials |
|---|---|
| Definition / diagnosis |
|
| Epidemiology / risks |
|
| Core mechanism |
|
| Clinical picture |
|
| Investigations |
|
| Management |
|
| Complications |
|
| Prevention / follow-up |
|
| Exam traps |
|
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) — Imprinting, UPD, and Russell-Silver syndrome sections
[2] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 498–500, 510) — RSS clinical features, imprinting mechanisms, short stature approach, rare disease diagnostics
[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 498–500, 510) — RSS clinical features, GH replacement, short stature approach, rare disease management
[4] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 500) — RSS clinical features (feeding difficulty, hypoglycaemia, body asymmetry, scoliosis, GU anomalies, developmental delay with normal intelligence, short stature)
Silver-Russell Syndrome (RSS)
Silver-Russell syndrome (RSS) — sometimes called Russell-Silver syndrome — is a clinically heterogeneous imprinting disorder characterised by severe intrauterine growth restriction (IUGR), poor postnatal growth, relative macrocephaly, a distinctive triangular facial gestalt, and body asymmetry [1][2].
Breaking down the name:
- Silver (Henry Silver, 1953) and Russell (Alexander Russell, 1954) independently described children with low birth weight, short stature, and characteristic facial features.
- The eponymous syndrome recognises the overlap between their two cohorts.
Phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age [2].
Core Concept
RSS is the clinical mirror image of Beckwith-Wiedemann syndrome (BWS). Both involve imprinting disturbances at chromosome 11p15.5, but in opposite directions: RSS = undergrowth; BWS = overgrowth. Understanding this reciprocal relationship is the key to understanding the molecular pathogenesis.
| Feature | Detail |
|---|---|
| Incidence | ~1/3,000 – 1/100,000 live births (wide range reflects diagnostic heterogeneity) [1] |
| Sex ratio | M = F (no sex predilection) [1] |
| Ethnic predilection | None documented; described worldwide |
| Most common genetic cause of IUGR | Yes — RSS is considered the most common genetic cause of IUGR [1] |
- True prevalence is likely underestimated because milder phenotypes go unrecognised, and molecular confirmation is only obtained in ~60% of clinically suspected cases.
- Hong Kong context: RSS is a rare disease but is increasingly recognised with wider availability of methylation-specific testing. The Hospital Authority rare-disease registry and Clinical Genetic Service at QMH/CUHK handle most referrals.
3. Relevant Anatomy, Physiology and Growth Concepts
To understand RSS you must first understand what drives normal growth:
- Fetal growth is primarily driven by insulin and insulin-like growth factors (IGF-1, IGF-2), placental nutrient supply, and genetic factors. IGF-2 is particularly important in fetal growth.
- Postnatal growth shifts to depend more on growth hormone (GH) → IGF-1 axis, nutrition, and thyroid hormone.
- Imprinted genes — including IGF-2 — fine-tune the balance between fetal growth-promoting (paternally expressed) and growth-restraining (maternally expressed) signals.
Imprinting: gene expression influenced by the sex of the parent who transmits it (i.e., one allele is epigenetically "switched off") [1].
- Most human genes are expressed from both parental alleles (biallelic expression).
- ~100 known imprinted genes to date; they often cluster in imprinting control regions (ICRs) rich in CpG islands [1].
- The "switch" is DNA methylation at ICRs:
The 11p15.5 Imprinting Region
This region contains two imprinting control domains:
| Domain | ICR | Key Gene(s) | Normally Expressed From | Effect |
|---|---|---|---|---|
| Domain 1 (telomeric) | ICR1 (H19/IGF2) | IGF-2 (growth promoter), H19 (growth suppressor) | Paternal allele expresses IGF-2; Maternal allele expresses H19 | Balances fetal growth |
| Domain 2 (centromeric) | ICR2 (KvDMR1) | CDKN1C, KCNQ1OT1 | Maternal allele expresses CDKN1C (growth suppressor) | Restrains fetal growth |
In normal physiology:
- The paternal copy of ICR1 is methylated → silences H19 → allows IGF-2 expression → promotes growth.
- The maternal copy of ICR1 is unmethylated → H19 is expressed and acts as an insulator blocking IGF-2 expression → restrains growth.
This beautiful balance means the fetus gets exactly the right amount of IGF-2.
Chromosome 7 harbours imprinted genes (e.g., GRB10, MEST/PEG1) involved in growth regulation. Maternal uniparental disomy of chromosome 7 (matUPD7) leads to loss of paternally expressed growth-promoting genes → growth restriction.
4. Aetiology and Pathophysiology
RSS is genetically heterogeneous, but ~60% are associated with imprinting regions on chromosomes 7 and 11 [1].
| Mechanism | Frequency | Chromosome | Pathophysiology |
|---|---|---|---|
| H19/IGF2 ICR1 hypomethylation (loss of methylation, LOM) | ~40–50% | 11p15.5 | Loss of methylation on the paternal ICR1 → paternal allele now behaves like the maternal allele → both alleles express H19 and neither expresses IGF-2 → ↓↓ IGF-2 → severe fetal undergrowth |
| Maternal UPD of chromosome 7 (matUPD7) | ~5–10% | 7 | Two maternal copies, no paternal copy → loss of paternally expressed growth genes (e.g., MEST) → growth restriction + possible mild developmental delay |
| Maternal duplication 11p15.5 | Rare | 11p15.5 | Extra copy of maternal (growth-suppressive) alleles → net ↓ IGF-2 effect |
| Other rare causes | ~40% remain molecularly unconfirmed | Various (14q32, HMGA2, PLAG1, etc.) | Emerging evidence of additional loci |
"Opposite epimutations, namely hypermethylation on the same region on chromosome 11p15.5, will lead to Beckwith-Wiedemann syndrome (BWS)" [2].
The Mirror Concept (high-yield):
- Paternal allele expressive + Maternal allele silenced → Big baby (BWS)
- Paternal allele silenced + Maternal allele expressive → Small baby (RSS) [2]
High Yield – RSS vs BWS
Think of it as a see-saw: IGF-2 on one side (growth), H19/CDKN1C on the other (restraint).
- RSS = the growth side is down (↓ IGF-2) → small baby
- BWS = the growth side is up (↑ IGF-2) → big baby with organomegaly and tumour risk
| Feature | ICR1 LOM (11p15.5) | matUPD7 |
|---|---|---|
| Severity of IUGR | More severe | Milder |
| Body asymmetry | More common | Less common |
| Feeding difficulties | Prominent | Prominent |
| Speech/learning | Usually normal intelligence | Myoclonus-dystonia, speech delay more common |
| Relative macrocephaly | Very prominent | Present but less marked |
5. Classification
This is the most clinically relevant classification.
Examples of imprinting disorders: Prader-Willi, Angelman, Silver-Russell, Beckwith-Wiedemann [1].
Pathological causes of short stature — "PICNICS" mnemonic: [3]
- P — Psychological (deprivation)
- I — Iatrogenic (glucocorticoid usage, spinal radiation)
- C — Chronic illness
- N — Nutritional
- I — IUGR (unknown aetiology or part of a syndrome, e.g., Russell-Silver syndrome)
- C — Chromosomal (Turner syndrome, Noonan syndrome, Down syndrome, Prader-Willi syndrome)
- S — Skeletal dysplasia (achondroplasia, hypochondroplasia)
- + Endocrine — hypothyroidism, growth hormone deficiency, Cushing syndrome [3]
6. Clinical Features
| Symptom | Pathophysiological Basis |
|---|---|
| Small baby at birth (low birth weight, short birth length) | Severe IUGR due to ↓ IGF-2 → reduced fetal growth. Birth weight typically < 10th centile, often < 3rd centile |
| Feeding difficulty in infancy | Multifactorial: micrognathia → poor oral feeding mechanics; high caloric demand relative to body size; gastro-oesophageal reflux common; relative caloric insufficiency for catch-up growth |
| Hypoglycaemia (hypoGly) | Reduced glycogen stores (very small for age) + relatively large brain (high glucose consumer) + poor feeding = neonatal/infantile hypoglycaemia. This can be dangerous and requires monitoring |
| Poor weight gain / failure to thrive | Persistent growth restriction: RSS children do not show the typical "catch-up growth" that most SGA babies achieve by 2 years |
| Short stature (< –2 SD) | Ongoing postnatal growth failure from ↓ IGF-2 and overall growth gene dysregulation. Special growth charts are available for RSS [1] |
| Excessive sweating (especially nocturnal) | Related to hypoglycaemia or autonomic dysregulation; common in infancy |
| Developmental delay (motor) — but normal intelligence [1] | Hypotonia + feeding difficulties → motor milestones may be delayed. Cognitive outcome is usually normal, though matUPD7 subtype may have speech delay |
| Dental problems (crowding, malocclusion) | Micrognathia → small jaw cannot accommodate normal-sized teeth |
6.2 Signs (what the clinician finds on examination)
| Sign | Pathophysiological Basis |
|---|---|
| IUGR and low birth weight [1][2] | ↓ IGF-2 → inadequate fetal growth |
| Short stature < –2 SD [1] | Persistent postnatal growth failure |
| Relative macrocephaly | "Normal head circumference but appears large due to small body size" [1] — the brain is relatively spared compared to somatic growth. Head circumference is usually normal or mildly reduced, but the body is disproportionately small, creating the appearance of a large head |
| Low BMI / lean habitus | Reduced subcutaneous fat and muscle mass; high metabolic rate relative to size |
| Sign | Pathophysiological Basis |
|---|---|
| Triangular face | Broad forehead contrasting with micrognathia (small mandible) creates the classic inverted-triangle shape [1] |
| Broad/prominent forehead | Relative macrocephaly with frontal bossing |
| Micrognathia (small jaw) | Underdevelopment of mandible — contributes to feeding difficulties and dental crowding |
| Downturned corners of mouth [1] | Characteristic — gives a "sad" or "shark-mouth" appearance |
| Thin lips | Part of the facial gestalt |
| Blue sclerae | Thin sclera from connective tissue involvement (not always present) |
| Low-set/posteriorly rotated ears | Craniofacial developmental field defect |
| Sign | Pathophysiological Basis |
|---|---|
| Body asymmetry (hemihypertrophy/hemihypotrophy) | "May involve face/trunk/limb" [1] — one side of the body grows less than the other. This reflects mosaic epigenetic changes. Note: in RSS this is technically hemihypotrophy (one side smaller) rather than true hemihypertrophy. Asymmetry is more common in the ICR1 LOM subtype |
| Clinodactyly of the 5th finger [1] | Inward curving of the 5th (little) finger due to a trapezoidal or delta-shaped middle phalanx. This is a minor anomaly seen in several genetic syndromes |
| Syndactyly of 2nd and 3rd toes | Minor limb anomaly, variably present |
| Small hands/feet | Proportionate undergrowth |
| Sign | Pathophysiological Basis |
|---|---|
| Hypotonia [1] | Central/peripheral hypotonia → contributes to feeding difficulty and motor delay |
| Scoliosis [1] | Asymmetric growth of vertebral bodies ± hypotonia → spinal curvature |
| Genitourinary anomalies: cryptorchidism, hypospadias [1] | Incomplete testicular descent and urethral anomaly — likely related to overall growth gene dysregulation affecting genital development |
| Café-au-lait spots (occasionally) | Non-specific; may be seen in mosaic cases |
| Precocious puberty (relative or central) | Premature adrenarche may occur; children with RSS may enter puberty early relative to their bone age, which can compromise final adult height further |
Classic Clinical Vignette for Exams
A newborn or infant presents with:
- IUGR / SGA (small-for-gestational-age) who fails to show catch-up growth
- Triangular face with broad forehead and small chin
- Relative macrocephaly (head looks big but HC is normal)
- Body asymmetry (one leg shorter than the other)
- Clinodactyly of the 5th finger
- Feeding difficulties and hypoglycaemia
→ Think Silver-Russell Syndrome
| Age | Key Features |
|---|---|
| Neonate | SGA, triangular face, feeding difficulty, hypoglycaemia, hypotonia |
| Infancy | Failure to thrive, persistent feeding problems, excessive sweating, motor delay |
| Early childhood | Short stature becomes evident, body asymmetry more obvious, clinodactyly, speech delay (esp. matUPD7) |
| Later childhood | Premature adrenarche possible → risk of early puberty compromising final height |
| Adolescence/Adulthood | Facial features and asymmetry usually become more subtle [2]; final adult height typically 148–155 cm (male) or 139–148 cm (female) without GH treatment |
| Condition | Mechanism / Relevance |
|---|---|
| Hypoglycaemia | As above — must be actively screened in infancy; fasting tolerance is reduced |
| Gastro-oesophageal reflux | Small body, oesophageal dysmotility |
| Premature adrenarche / early puberty | May compromise final height — an indication for GnRH analogue therapy |
| Learning difficulties (minority) | Especially matUPD7 subtype; speech delay |
| Orthopaedic issues | Limb-length discrepancy, scoliosis |
| Dental malocclusion | Micrognathia → orthodontic intervention often needed |
| Psychosocial impact | Short stature, facial appearance → body image concerns; family support essential |
RSS falls under "dysmorphism with a recognizable syndrome" [4] and "rare diseases among common diseases" [5] in the GC lecture framework.
A systematic approach in paediatrics:
- Growth assessment: Plot on growth chart — weight, length/height, head circumference. Look for discrepancy between HC (normal) and body size (small) = relative macrocephaly.
- Dysmorphology examination: Triangular face, clinodactyly, body asymmetry — photograph and document.
- Feeding and nutritional history: Detailed — caloric intake, GOR symptoms, hypoglycaemia episodes.
- Developmental assessment: Milestones — motor (often delayed), speech (delayed in matUPD7), cognition (usually normal).
- Family history: Usually sporadic, but assess for consanguinity and family members with growth issues.
- Molecular testing: Methylation-specific analysis at 11p15.5 (ICR1) and matUPD7 testing — this will be covered in the Diagnosis section.
Management overview (to be covered in detail in Part 2): GH replacement is the primary growth-promoting treatment [1]. Additional management includes nutritional support, hypoglycaemia prevention, orthopaedic follow-up, and monitoring for premature adrenarche.
| Aspect | Key Points |
|---|---|
| Definition | Imprinting disorder with IUGR, postnatal growth failure, triangular face, asymmetry |
| Incidence | 1/3,000–100,000 |
| Most common molecular cause | H19/IGF2 ICR1 hypomethylation at 11p15.5 (~40–50%) |
| Mirror syndrome | BWS (same locus, opposite epimutation) |
| Pathophysiology | ↓ IGF-2 → ↓ fetal and postnatal growth |
| Classic triad | IUGR + relative macrocephaly + triangular face |
| High-risk complications | Hypoglycaemia, failure to thrive, premature puberty |
| Treatment | GH replacement, nutritional support |
High Yield Summary
-
RSS is the most common genetic cause of IUGR — always consider it in an SGA baby who fails to catch up.
-
Molecular basis: ~40–50% have ICR1 hypomethylation at 11p15.5 (↓ IGF-2); ~5–10% have matUPD7; ~40% remain molecularly unconfirmed.
-
RSS and BWS are mirror syndromes: Same locus (11p15.5), opposite epimutations. RSS = undergrowth, BWS = overgrowth.
-
PICNICS mnemonic for pathological short stature — RSS falls under "I" (IUGR as part of a syndrome).
-
Classic clinical features: Triangular face (broad forehead + micrognathia), relative macrocephaly, body asymmetry, clinodactyly of 5th finger, feeding difficulty, hypoglycaemia.
-
Relative macrocephaly means the head circumference is NORMAL but appears large because the body is disproportionately small.
-
GH replacement is the mainstay of growth treatment.
-
Hypoglycaemia is a dangerous early complication — monitor and manage aggressively.
-
Premature adrenarche may compromise final height → consider GnRH analogue if true precocious puberty develops.
-
Facial features and asymmetry become more subtle with age — diagnosis is easier in early childhood.
Active Recall - Silver-Russell Syndrome (Definition, Epidemiology, Aetiology, Clinical Features)
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) — Imprinting, UPD, and Russell-Silver syndrome sections [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 855) — Russell-Silver syndrome overview and genetics [3] GC lecture slides: CFB (PAE02) Child growth and development.pdf (p. 23) — PICNICS mnemonic, pathological causes of short stature [4] GC lecture slides: CFB (PAE02) Child growth and development.pdf (pp. 33–34) — Dysmorphism with a recognizable syndrome, Russell-Silver syndrome [5] GC lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 6) — Rare diseases among common diseases, Russell-Silver syndrome listed
Differential Diagnosis of Silver-Russell Syndrome
Silver-Russell syndrome is not diagnosed by a single lab test or pathognomonic sign. It presents as a constellation of features — IUGR/SGA with failure of catch-up growth, a characteristic facial gestalt, body asymmetry, and feeding difficulty. Each of these features individually overlaps with many other conditions. The clinician's job is to systematically differentiate RSS from other causes of:
- Intrauterine growth restriction / small-for-gestational-age (SGA) with persistent short stature
- Dysmorphic syndromes with short stature
- Body asymmetry (hemihypertrophy/hemihypotrophy)
- Feeding difficulty with failure to thrive in infancy
- Relative macrocephaly in a small child
The PICNICS framework from the GC lectures is the backbone for organising the differential of short stature [3]:
Pathological causes of short stature — PICNICS: [3]
- P — Psychological (deprivation)
- I — Iatrogenic (glucocorticoid usage, spinal radiation)
- C — Chronic illness
- N — Nutritional
- I — IUGR (unknown aetiology or part of a syndrome, e.g., Russell-Silver syndrome)
- C — Chromosomal (Turner syndrome, Noonan syndrome, Down syndrome, Prader-Willi syndrome)
- S — Skeletal dysplasia (achondroplasia, hypochondroplasia)
- + Endocrine — hypothyroidism, growth hormone deficiency, Cushing syndrome [3]
Systematic Differential Diagnosis
I'll organise the DDx into logical groups based on the dominant presenting feature that overlaps with RSS.
These are the most conceptually important differentials because they share the same molecular mechanism class — genomic imprinting disturbances [1][6].
| Condition | Chromosome | Mechanism | Key Overlapping Features | Key Distinguishing Features |
|---|---|---|---|---|
| Beckwith-Wiedemann syndrome (BWS) | 11p15.5 | Hypermethylation of ICR1 (opposite to RSS) or paternal UPD11 [2][6] | Same locus (11p15.5); hemihypertrophy; hypoglycaemia | Mirror image of RSS: macrosomia, macroglossia, omphalocele, visceromegaly, overgrowth, embryonal tumour risk (Wilms) [6]. BWS = BIG baby; RSS = SMALL baby |
| Prader-Willi syndrome (PWS) | 15q11-13 | Loss of paternal copy (microdeletion 60%, maternal UPD 35%) [1][6] | Neonatal feeding difficulty, hypotonia, short stature, GH treatment | Hyperphagia leading to obesity in later childhood; almond-shaped eyes, small hands/feet; moderate ID; narrow bitemporal diameter. PWS children transition from FTT → obesity; RSS children remain thin [1][6] |
| Angelman syndrome | 15q11-13 | Loss of maternal copy (UBE3A) [1][6] | Feeding difficulty, hypotonia | Frequent laughter/smiling, severe ID, microcephaly, seizures, ataxia, hand flapping. No growth restriction phenotype like RSS [1][6] |
High Yield — Imprinting Disorder Comparison
The four classic imprinting disorders you must know: Prader-Willi, Angelman, Silver-Russell, Beckwith-Wiedemann [1].
Key distinguishing principle:
- Chr 11p15.5: RSS (hypomethylation → small) vs BWS (hypermethylation → big)
- Chr 15q11-13: PWS (loss of paternal → hyperphagia/obesity) vs Angelman (loss of maternal → happy puppet/seizures)
These are the conditions listed under "Chromosomal" and "Dysmorphism with a recognizable syndrome" in the PICNICS framework [3][4].
| Condition | Key Overlapping Features with RSS | Key Distinguishing Features | Why It's Different |
|---|---|---|---|
| Turner syndrome (45,X) [3][7] | Short stature, occasionally body asymmetry, lymphoedema at birth | Webbed neck, low hairline, cubitus valgus, widely spaced nipples, coarctation of aorta, streak gonads; only affects females; SHOX haploinsufficiency causes the short stature [7] | RSS affects M=F; Turner has characteristic left-sided cardiac lesions and gonadal dysgenesis. Karyotype is diagnostic. |
| Noonan syndrome [3][7] | Short stature, feeding difficulty in infancy, cryptorchidism | Turner-like facies but affects both sexes; ptosis, downslanting palpebral fissures, hypertelorism, low-set ears; right-sided cardiac lesions (pulmonary stenosis, HCM); RASopathy [7] | RSS has triangular face and body asymmetry; Noonan has characteristic cardiac defects and is a RASopathy |
| Down syndrome (Trisomy 21) [3][7] | Short stature, hypotonia, clinodactyly | Flat facies, upslanting palpebral fissures, epicanthic folds, single palmar crease, intellectual disability; AVSD [7] | Karyotype 47,+21 is diagnostic. Down has moderate-severe ID; RSS usually has normal intelligence |
| 3M syndrome | Severe pre- and postnatal growth restriction, relative macrocephaly | Autosomal recessive (CUL7, OBSL1, CCDC8 mutations); no body asymmetry; facial features differ (fleshy nose tip, long philtrum, anteverted nares) | Important DDx because growth restriction and relative macrocephaly overlap significantly; molecular testing differentiates |
| Mulibrey nanism | Prenatal and postnatal growth failure, triangular face | "MUscle-LIver-BRain-EYe" involvement; constrictive pericarditis; autosomal recessive (TRIM37) | Pericardial disease and hepatomegaly distinguish it from RSS |
Most SGA babies (> 85%) show catch-up growth by age 2. Those who don't form an important differential:
| Condition | Key Features | How to Distinguish from RSS |
|---|---|---|
| Idiopathic SGA without catch-up | Born SGA, remains short, no dysmorphic features | No triangular face, no body asymmetry, no clinodactyly. This is a diagnosis of exclusion after syndromic causes are ruled out. May still benefit from GH therapy |
| Placental insufficiency-related IUGR | Maternal pre-eclampsia, smoking, substance use → SGA | History of maternal risk factors; infant usually shows catch-up growth; no dysmorphic features |
| Congenital infections (TORCH) | SGA, microcephaly, hepatosplenomegaly | Microcephaly (true, not relative macrocephaly), intracranial calcifications, chorioretinitis, hepatosplenomegaly; TORCH screen positive |
| Fetal alcohol spectrum disorder (FASD) | Growth restriction, facial dysmorphism | Smooth philtrum, thin upper lip, short palpebral fissures; history of maternal alcohol use; microcephaly (not relative macrocephaly); neurobehavioural problems |
Body asymmetry narrows the differential significantly because only certain conditions produce it:
| Condition | Type of Asymmetry | Key Distinguishing Features |
|---|---|---|
| RSS | Hemihypotrophy (one side smaller) [1] | Growth restriction + triangular face + clinodactyly |
| BWS | Hemihypertrophy (one side larger) [6] | Overgrowth + macroglossia + omphalocele; tumour risk |
| Isolated hemihypertrophy | One side larger, no other syndromic features | No IUGR, no facial dysmorphism; still needs tumour surveillance (Wilms, hepatoblastoma) |
| Klippel-Trénaunay syndrome | Limb hypertrophy with capillary malformation and varicose veins | Vascular malformation is the hallmark; no growth restriction |
| Neurofibromatosis type 1 (NF1) [8] | Limb asymmetry from plexiform neurofibromas or tibial dysplasia | Café-au-lait macules ≥6, axillary freckling, neurofibromas, Lisch nodules [8] |
These are conceptually easy to distinguish from RSS because endocrine causes typically produce a "short and fat" phenotype (weight > height centile), whereas RSS produces a "short and thin" phenotype [1].
| Condition | Why It Differs from RSS |
|---|---|
| Growth hormone deficiency [3] | Proportionate short stature but increased truncal adiposity; no IUGR (GH is not the primary driver of fetal growth); normal facial features; low IGF-1/GH on stimulation testing |
| Hypothyroidism [3] | Short stature + weight gain, constipation, dry skin, delayed bone age, coarse facies; TFT diagnostic |
| Cushing syndrome [3] | Truncal obesity, moon facies, striae, hypertension; cortisol studies diagnostic |
| Pseudohypoparathyroidism (Albright hereditary osteodystrophy) | Short stature, obesity, round face, short 4th metacarpal, subcutaneous calcifications; ↑PTH with ↓Ca |
Key Clinical Pearl
Causes of short stature by appearance [1]:
- Dysmorphism: Down, Turner, Noonan, Russell-Silver
- Disproportionately short: Skeletal dysplasia, storage disorders
- Short and thin: Chronic illness, malnutrition, malignancy, psychosocial deprivation
- Short and fat: Endocrine causes (GH deficiency, hypothyroidism, Cushing, Prader-Willi)
RSS falls under dysmorphism AND short and thin — the body habitus is lean with reduced subcutaneous fat, which immediately distinguishes it from endocrine causes.
These cause disproportionate short stature, which is different from RSS (proportionate short stature with relative macrocephaly):
| Condition | Key Distinguishing Features |
|---|---|
| Achondroplasia [3] | Rhizomelic limb shortening, macrocephaly (true), frontal bossing, trident hand; FGFR3 mutation; disproportionate |
| Hypochondroplasia [3] | Milder form of achondroplasia; disproportionate short stature; FGFR3 |
| Spondyloepiphyseal dysplasia | Trunk > limb shortening; kyphoscoliosis; skeletal survey diagnostic [1] |
| Feature | RSS | BWS | PWS | Turner | Noonan | 3M | FASD |
|---|---|---|---|---|---|---|---|
| Growth | IUGR, SGA, FTT | Macrosomia, overgrowth | Short, obese | Short | Short | Very short | SGA |
| Face | Triangular, broad forehead, micrognathia | Macroglossia | Almond eyes, narrow bitemporal | Normal to mild dysmorphism | Ptosis, hypertelorism | Fleshy nose | Smooth philtrum, thin lip |
| Head | Relative macrocephaly | Normal/large | Dolichocephaly | Normal | Normal | Relative macrocephaly | Microcephaly |
| Body asymmetry | Yes (hemihypotrophy) | Yes (hemihypertrophy) | No | Rarely | No | No | No |
| Cardiac | No | No | No | Left-sided | Right-sided | No | VSD, ASD |
| Intelligence | Normal | Normal | Mild-moderate ID | Normal (unless mosaic) | Variable | Normal | Impaired |
| Molecular | 11p15.5 LOM / matUPD7 | 11p15.5 GOM / patUPD11 | 15q11 del / matUPD15 | 45,X | RAS pathway | CUL7/OBSL1 | Clinical Dx |
High Yield Exam Points — Differential Diagnosis
-
RSS and BWS are mirror syndromes at 11p15.5 — opposite epimutations, opposite phenotypes. This is the single most examined molecular concept.
-
PICNICS is the GC lecture framework for short stature DDx — RSS = "I" (IUGR part of a syndrome).
-
Causes of short stature by appearance: Dysmorphic (RSS, Turner, Noonan, Down), Disproportionate (skeletal dysplasia), Short-and-thin (chronic illness, malnutrition), Short-and-fat (endocrine) [1].
-
Relative macrocephaly (HC normal, body small) differentiates RSS from true macrocephaly conditions and from FASD/TORCH (which cause microcephaly).
-
Body asymmetry in a growth-restricted child = think RSS first. Body asymmetry in an overgrown child = think BWS.
-
Endocrine causes are "short and fat" — the opposite body habitus to RSS ("short and thin").
-
Among imprinting disorders: know the chromosome, which parental copy is lost, and the clinical consequence for PWS, Angelman, RSS, and BWS.
Active Recall - Differential Diagnosis of Silver-Russell Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 498–500, 507, 510) — Short stature approach, imprinting disorders, RSS, Turner syndrome, paediatric syndromes table [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 855) — RSS genetics and BWS mirror concept [3] GC lecture slides: CFB (PAE02) Child growth and development.pdf (p. 23) — PICNICS mnemonic, pathological causes of short stature [4] GC lecture slides: CFB (PAE02) Child growth and development.pdf (pp. 33–34) — Dysmorphism with a recognizable syndrome, Russell-Silver syndrome [5] GC lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 6) — Rare diseases among common diseases [6] Senior notes: Maksim Paediatric Notes.pdf (p. 207) — Genomic imprinting disorders comparison table (PWS, Angelman, BWS, RSS) [7] Senior notes: Ryan Ho Cardiology.pdf (p. 185) — Common syndromes associated with congenital heart diseases (Down, Turner, Noonan, DiGeorge, Williams) [8] Senior notes: Ryan Ho Rheumatology.pdf (p. 172) — NF1 diagnostic criteria and differential
Diagnostic Criteria for Silver-Russell Syndrome
RSS is genetically heterogeneous — molecular confirmation is only achievable in ~60% of clinically suspected cases [1]. This means a substantial proportion of patients with the clinical phenotype will have negative molecular testing. Therefore, the diagnosis of RSS rests on a clinical scoring system first, with molecular testing used for confirmation and subtype classification rather than as the sole gatekeeper.
Think of it like this: the clinical criteria tell you who to test, and the molecular result tells you the subtype and guides prognosis/genetic counselling.
The Netchine-Harbison Clinical Scoring System (NH-CSS) is the internationally accepted clinical diagnostic framework for RSS, endorsed by the First International Consensus Statement on RSS (2017, Wakeling et al.) and remains current as of 2025 [9].
Clinical diagnosis of RSS requires at least 4 out of 6 NH-CSS criteria:
| # | Criterion | Definition / Cut-Off | Pathophysiological Basis |
|---|---|---|---|
| 1 | SGA (birth weight and/or birth length) | ≤ –2 SDS for gestational age | ↓ IGF-2 → reduced fetal growth |
| 2 | Postnatal growth failure | Height at 24 months ≤ –2 SDS or height ≤ –2 SDS below mid-parental target height | Persistent growth restriction without catch-up; ongoing growth gene dysregulation |
| 3 | Relative macrocephaly at birth | Head circumference ≥ 1.5 SDS above birth weight and/or length SDS | Brain relatively spared from somatic growth restriction → HC appears disproportionately large |
| 4 | Protruding/prominent forehead (age 1–3 years) | Forehead projects anterior to facial plane as viewed in profile | Part of the triangular face gestalt; frontal bossing from relative macrocephaly |
| 5 | Body asymmetry | Leg length discrepancy ≥ 0.5 cm or arm asymmetry or LLD that is documented but < 0.5 cm plus ≥2 other asymmetric body parts | Mosaic epigenetic changes → differential growth of body segments |
| 6 | Feeding difficulties and/or low BMI | BMI ≤ –2 SDS at 24 months OR current use of enteral feeding support (e.g., NGT, gastrostomy) or cyproheptadine for appetite stimulation in first 4 years of life | Micrognathia → poor oral mechanics; high metabolic demand relative to size; GOR; reduced caloric intake |
High Yield — NH-CSS Scoring Rule
Clinical RSS = ≥ 4 out of 6 NH-CSS criteria met → proceed to molecular testing.
If only 4 criteria are met and molecular testing is negative, the diagnosis remains "clinical RSS" (phenotypic diagnosis without molecular confirmation). This is valid because ~40% of clinically diagnosed RSS patients have no identifiable molecular cause [9].
Once clinical criteria are met (≥4/6 NH-CSS), molecular testing is performed in a stepwise fashion:
| Test | What It Detects | Expected Finding in RSS | Frequency |
|---|---|---|---|
| Step 1: Methylation analysis at 11p15.5 (ICR1) | H19/IGF2 ICR1 hypomethylation (loss of methylation, LOM) | Reduced methylation at the paternal ICR1 allele | ~40–50% of all RSS [1][2] |
| Step 2: Microsatellite analysis or SNP array for matUPD7 | Maternal uniparental disomy of chromosome 7 | Two maternal copies of chromosome 7, no paternal copy | ~5–10% [1][6] |
| Step 3 (if steps 1–2 negative): Extended testing | Rare causes — 14q32 abnormalities, CDKN1C mutations, HMGA2/PLAG1 mutations, CNVs | Various | Individually rare, collectively ~5% |
| Step 4 (research/clinical): Whole exome/genome sequencing | Novel genetic causes | Identifies pathogenic variants in newly described genes | Applied in molecularly unresolved cases |
RSS is genetically heterogeneous, but ~60% are associated with imprinting regions on chromosomes 7 and 11 — e.g., H19 hypomethylation, matUPD7, matdup11p15.5 [1]
Understanding why methylation testing is the first-line molecular test:
- DNA methylation = addition of a methyl group (–CH₃) to cytosine at CpG dinucleotides → methylation makes DNA more tightly bound → ↓ expression [1].
- In RSS, the paternal ICR1 at 11p15.5 should be methylated (allowing IGF-2 expression). When this methylation is lost (hypomethylation/LOM), IGF-2 is silenced → ↓ growth.
- Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) is the standard method:
- It simultaneously detects methylation status AND copy number changes at 11p15.5
- A single test can identify ICR1 LOM, ICR2 abnormalities (important for excluding BWS), and duplications/deletions
- If MS-MLPA at 11p15.5 is normal → proceed to matUPD7 testing using microsatellite markers or SNP array comparing parental and child DNA
Why Karyotype and Standard Genetic Tests Are NOT Sufficient
A standard karyotype will be normal in RSS — it cannot detect epigenetic (methylation) changes or UPD. Similarly, chromosomal microarray (CMA) alone will miss hypomethylation (though it can detect copy number changes and large UPD). You must specifically request methylation-specific testing. This is a common conceptual error.
Investigation Modalities — Systematic Approach
Beyond molecular diagnosis, a child with RSS needs a comprehensive workup to assess complications and guide management. This follows the general paediatric principle of less invasive → more invasive [10].
| Investigation | Key Findings in RSS | Interpretation |
|---|---|---|
| Serial height/weight/HC measurements plotted on growth chart | Height and weight ≤ –2 SDS; HC normal or mildly reduced but disproportionately large relative to body | "Always plot on growth chart: compare with weight centile, compare with mid-parental centile, does it follow or cross centile?" [1]. RSS children track well below the 3rd centile. Special growth charts are available for RSS [1] |
| Mid-parental height (MPH) calculation | RSS child's height is well below the MPH target range | MPH: Male = (sum of parental heights + 13cm)/2; Female = (sum of parental heights – 13cm)/2; target range = ± 8.5cm [1] |
| Body proportions (sitting height, arm span, leg length discrepancy) | Limb length discrepancy ≥ 0.5 cm; may have truncal asymmetry | Quantifies asymmetry; used for NH-CSS criterion 5 and for orthopaedic follow-up |
| BMI calculation | BMI ≤ –2 SDS typical in infancy/early childhood | Confirms lean body habitus ("short and thin" phenotype) [1] |
| Investigation | Key Findings | Interpretation & Why |
|---|---|---|
| Blood glucose monitoring (bedside + lab) | Hypoglycaemia — fasting or postprandial | Critical in neonates and infants: reduced glycogen stores + large brain + poor feeding → hypoglycaemia risk. Monitor glucose especially during intercurrent illness. Prolonged fasting should be avoided |
| Insulin, C-peptide (if recurrent hypoglycaemia) | May show relative hyperinsulinism | Some RSS children have disproportionate insulin secretion relative to their small body mass |
| IGF-1 and IGFBP-3 | Often low-normal or low | Useful baseline before starting GH therapy. Low IGF-1 does not necessarily mean GH deficiency — RSS children may have GH sufficiency but reduced target gene expression |
| Thyroid function tests (TFT) | Usually normal | To exclude hypothyroidism as a co-existing or alternative cause of growth failure [3] |
| Coeliac screen (tTG-IgA) | Usually negative | To exclude coeliac disease as a cause of FTT — standard workup for any child with growth failure |
| Renal function, electrolytes | Usually normal | To exclude CKD as a cause of growth failure |
| Investigation | When to Perform | Key Findings | Interpretation |
|---|---|---|---|
| GH stimulation test (e.g., insulin tolerance test, glucagon stimulation, clonidine stimulation) | If GH deficiency is suspected clinically (very short + low growth velocity + low IGF-1) OR prior to starting GH therapy | Peak GH response may be normal or blunted | True GH deficiency is uncommon in RSS but can co-exist. Most RSS children are NOT GH-deficient but still benefit from GH therapy (approved for SGA without catch-up). The stimulation test helps classify the indication for GH as "SGA" vs "GHD" [10] |
| Bone age (left wrist X-ray) | Baseline and during GH therapy | Usually delayed (bone age < chronological age) | Delayed bone age means there is still growth potential. This is actually a favourable prognostic sign for GH treatment response |
| Adrenal function screening (morning cortisol, ACTH if indicated) | If hypoglycaemia is recurrent and unexplained | Usually normal | To exclude adrenal insufficiency as a cause of hypoglycaemia |
Important Concept — GH in RSS
Most RSS children are not GH-deficient. GH therapy in RSS is given under the SGA indication (children born SGA who fail to show catch-up growth by age 2–4 years, with height ≤ –2.5 SDS). The GH stimulation test is still often performed to:
- Exclude true GHD (which would change the dosing regimen)
- Satisfy regulatory/insurance requirements for GH prescription
- Establish baseline IGF-1 for monitoring
| Investigation | Key Findings | Interpretation |
|---|---|---|
| Skeletal survey or targeted X-rays | Clinodactyly (curved 5th finger — trapezoidal middle phalanx), limb length discrepancy, scoliosis | Quantifies skeletal anomalies. Not routinely indicated unless specific concerns; targeted imaging for scoliosis or limb asymmetry |
| Scanogram (standing leg-length X-ray) | Leg length discrepancy — may be ≥ 0.5 cm | Important for orthopaedic planning (shoe lift, epiphysiodesis consideration in older children) |
| Spinal X-ray | Scoliosis | Monitor during growth, especially during GH therapy which may accelerate growth asymmetrically |
| Investigation | Key Findings | Interpretation |
|---|---|---|
| Developmental assessment (Griffiths/Bayley scales) | Motor delay common; cognitive development usually normal [1] | Motor delay is multifactorial: hypotonia + feeding difficulty + small body. Cognitive reassurance is important for families |
| Speech and language assessment | May be delayed, especially in matUPD7 subtype | matUPD7 is associated with speech and language difficulties — early speech therapy referral |
| Feeding assessment (SLT + dietitian) | Oral motor dysfunction, GOR, poor caloric intake | Guides feeding strategy (texture modification, NGT consideration, anti-reflux measures) |
| Investigation | Purpose | Expected Findings |
|---|---|---|
| Renal ultrasound | Screen for GU anomalies (cryptorchidism, renal anomalies) [1] | May show renal structural anomalies (rare) |
| Cardiac echocardiogram | Not routinely indicated (RSS is not typically associated with cardiac defects) | Usually normal — but may be done as part of dysmorphology workup |
| Dental assessment | Micrognathia → dental crowding, malocclusion | Early orthodontic referral |
| Phase | Tests | Purpose |
|---|---|---|
| Clinical scoring | NH-CSS (6 criteria) | Identify who needs molecular testing |
| Molecular — Step 1 | MS-MLPA at 11p15.5 | Detect ICR1 LOM (most common cause) |
| Molecular — Step 2 | matUPD7 testing | Detect second most common cause |
| Molecular — Step 3 | Extended panel / WES / WGS | Rare causes |
| Metabolic | Glucose, insulin, TFT, coeliac, renal | Exclude co-morbidities, monitor hypoglycaemia |
| Endocrine | IGF-1, IGFBP-3, ± GH stimulation test, bone age | Baseline for GH therapy, classify indication |
| Orthopaedic | Scanogram, spinal X-ray | Asymmetry and scoliosis monitoring |
| Developmental | Griffiths/Bayley, SLT, feeding assessment | Guide early intervention |
High Yield Summary — Diagnosis of RSS
-
NH-CSS is the clinical diagnostic tool: ≥ 4/6 criteria = clinical RSS → molecular testing.
-
First-line molecular test = MS-MLPA at 11p15.5 (detects ICR1 hypomethylation + copy number changes). If negative → matUPD7 testing.
-
~60% of clinically diagnosed RSS have a confirmable molecular cause [1]; ~40% remain molecularly unconfirmed but the clinical diagnosis still stands.
-
Standard karyotype will be NORMAL in RSS — you need methylation-specific testing. Do not rely on karyotype or CMA alone.
-
GH stimulation test is performed to classify the GH treatment indication (SGA vs GHD) — most RSS children are not GH-deficient.
-
Bone age is typically delayed → good prognostic sign for growth potential.
-
Always plot on growth chart, compare with weight centile and mid-parental centile [1] — this is the fundamental first step for any child with short stature.
-
RSS is a rare disease — challenging to diagnose due to relative rarity, age-dependent findings, sporadic occurrence, and biological variability/penetrance [1].
Active Recall - Diagnostic Criteria and Investigations for Silver-Russell Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 498–500, 510) — RSS clinical features, imprinting mechanisms, short stature approach, rare disease diagnostics [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 855) — RSS genetics, BWS mirror concept [3] GC lecture slides: CFB (PAE02) Child growth and development.pdf (p. 23) — PICNICS mnemonic, pathological causes of short stature [6] Senior notes: Maksim Paediatric Notes.pdf (p. 207) — Genomic imprinting disorders comparison table [9] International Consensus: Wakeling et al. (2017) "Diagnosis and management of Silver-Russell syndrome: first international consensus statement" — Netchine-Harbison Clinical Scoring System (NH-CSS) and molecular testing algorithm (referenced as current guideline, not from provided notes) [10] Senior notes: Block A - Introduction to Endocrine investigations.pdf (pp. 1, 3) — Sequence of investigations principle, endocrine workup approach [11] Senior notes: Ryan Ho Chemical Path.pdf (p. 33) — GH stimulation testing, insulin tolerance test
Management of Silver-Russell Syndrome
RSS management is fundamentally about optimising the growth and development of a child who is constitutionally small, while preventing and treating complications (hypoglycaemia, feeding failure, premature puberty, orthopaedic problems) and supporting the family. There is no cure — the epigenetic/genetic defect is permanent. Management is therefore:
- Multidisciplinary — paediatric endocrinology, genetics, dietetics, speech therapy, orthopaedics, developmental paediatrics, orthodontics, psychology
- Longitudinal — requires follow-up from birth through adolescence (and transition to adult care)
- Age-dependent — priorities shift as the child grows
- Family-centred — parents need education, genetic counselling, psychosocial support
RSS is classified as a rare disease [1][5] — and like most rare diseases, few specific treatment options exist and management is largely supportive + symptomatic.
Treatment Modalities — Detailed
1. Growth Hormone (GH) Therapy — The Cornerstone of Growth Management
Approach: GH replacement [1].
Growth hormone supplement — modest efficacy of GH treatment of individuals with Russell-Silver syndrome [2].
| Aspect | Detail |
|---|---|
| Primary indication | Children born SGA who fail to show catch-up growth by age 2–4 years, with height ≤ –2.5 SDS |
| Regulatory basis | GH is approved for the SGA without catch-up indication (not primarily as GHD replacement, since most RSS children are NOT GH-deficient) |
| Starting age | Typically age 2–4 years (may start as early as age 2 in severe cases; some guidelines suggest considering at age 1 if severe growth failure) |
| Rationale — why does GH work in a non-GHD child? | GH at supraphysiological doses increases IGF-1 levels → stimulates linear growth at the growth plate → partially compensates for the ↓ IGF-2 effect. It also improves body composition (↑ lean mass, ↓ fat) and may improve appetite and caloric efficiency |
| Parameter | Detail |
|---|---|
| Formulation | Recombinant human GH (rhGH) — subcutaneous injection |
| Dose for SGA indication | 35–70 mcg/kg/day (higher dose than for GHD, which uses ~25–50 mcg/kg/day) |
| Administration | Daily subcutaneous injection, typically at bedtime (to mimic physiological nocturnal GH peak) |
| Monitoring | IGF-1 levels (keep within +1 to +2 SDS for age), growth velocity, bone age annually, glucose homeostasis |
| Duration | Continue until near-final height achieved (growth velocity < 2 cm/year) or epiphyseal fusion |
| Outcome | Detail |
|---|---|
| Height gain | Average improvement of +1 to +1.5 SDS over pre-treatment projected height; final adult height typically improves by +5 to +8 cm compared to untreated RSS |
| Efficacy qualifier | "Modest efficacy" [2] — GH helps but does not normalise height. Final height remains below average |
| Body composition | Improved lean mass, reduced body fat |
| Bone age | May accelerate modestly — hence the importance of monitoring |
| Contraindication / Caution | Reason |
|---|---|
| Active malignancy | GH is a growth factor — theoretical concern for tumour promotion. Must screen and exclude before starting |
| Closed epiphyses | No growth potential remaining — GH would be futile |
| Uncontrolled diabetes | GH is a counter-regulatory hormone → can worsen glucose homeostasis |
| Severe obesity with sleep apnoea (mainly applies to PWS rather than RSS) | Not typically relevant in RSS (children are lean), but general GH contraindication |
| Scoliosis monitoring | GH-accelerated growth can worsen pre-existing scoliosis → orthopaedic co-management |
| RSS-specific caution: tumour surveillance | Associated neoplasms include hepatoblastoma, hepatocellular carcinoma, Wilms tumour, testicular seminoma, craniopharyngioma [2]. Although tumour risk in RSS is much lower than in BWS, children with 11p15 abnormalities warrant baseline abdominal USS and periodic surveillance, especially before and during GH therapy |
High Yield — GH in RSS vs BWS
Both RSS and BWS involve 11p15.5. BWS has a significant tumour risk (Wilms, hepatoblastoma) requiring formal tumour screening protocols. RSS has a much lower but non-zero tumour risk. The shared locus means clinicians must be aware of the overlap and monitor accordingly.
| Side Effect | Mechanism | Management |
|---|---|---|
| Injection-site reactions | Local tissue reaction | Rotate injection sites |
| Headache / raised intracranial pressure (benign intracranial hypertension) | Fluid retention → ↑ CSF pressure | Rare in children; fundoscopy if symptomatic; stop GH temporarily |
| Arthralgia / myalgia | Rapid growth → musculoskeletal strain | Usually self-limiting; dose adjustment |
| Insulin resistance / impaired glucose tolerance | GH is a counter-regulatory hormone → ↑ hepatic glucose output, ↓ peripheral glucose uptake | Monitor fasting glucose and HbA1c; particularly important in RSS (already at risk of metabolic issues) |
| Scoliosis progression | Accelerated asymmetric spinal growth | Regular spinal examination |
| Slipped capital femoral epiphysis (SCFE) | Rapid growth → shear stress on femoral physis | Monitor for hip/knee pain; urgent orthopaedic referral |
2. Nutritional Management and Hypoglycaemia Prevention
This is the most urgent management priority in the neonatal and infant period.
| Strategy | Detail | Age Group |
|---|---|---|
| Frequent small feeds | Prevents fasting hypoglycaemia; compensates for poor oral intake | Neonates, infants |
| Caloric fortification | Add caloric supplements to breast milk or formula (e.g., energy-dense formula, MCT oil, maltodextrin) | Infants |
| Nasogastric tube (NGT) feeding | For infants unable to maintain adequate oral intake; often needed for weeks to months | Neonates, infants with severe feeding difficulty |
| Gastrostomy | If prolonged NGT dependency (> 3–6 months) or severe oral motor dysfunction | Infants, toddlers — family discussion and consent essential |
| Anti-reflux measures | Upright positioning, thickened feeds, proton pump inhibitor (e.g., omeprazole 1 mg/kg/day) if significant GORD | Infants |
| Cyproheptadine (appetite stimulant) | Antihistamine with serotonin antagonist properties → stimulates appetite | Toddlers, early childhood — used off-label; mentioned in NH-CSS criterion 6 |
| Dietitian involvement | Optimise caloric intake, monitor growth, guide weaning | All ages |
| Principle | Detail |
|---|---|
| Prevention | Avoid prolonged fasting; provide bedtime snack with complex carbohydrates (uncooked cornstarch in older children); emergency feeding plan for intercurrent illness |
| Monitoring | Bedside glucose checks during illness, pre-feeds in neonates |
| Acute treatment | Oral glucose gel (if conscious), IV 10% dextrose bolus (2–5 mL/kg) then maintenance infusion (if unable to feed) |
| Sick-day rules | Families must be educated: during fever or vomiting → more frequent feeds, early medical review if unable to tolerate oral intake |
Critical Safety Point
Hypoglycaemia is the most dangerous acute complication in RSS infants. It can cause seizures and permanent brain injury. Parents must be educated about sick-day management, signs of hypoglycaemia (sweating, pallor, irritability, lethargy, seizures), and when to seek emergency care. Written emergency plans should be provided.
3. Management of Premature Adrenarche and Precocious Puberty
RSS children may develop premature adrenarche (early adrenal androgen production) and in some cases true central precocious puberty (CPP). Early puberty → early epiphyseal fusion → compromised final adult height — which is already reduced. Therefore, identifying and treating early puberty is critical for height optimisation.
| Scenario | Management |
|---|---|
| Premature adrenarche alone (pubic/axillary hair before age 8 in girls / 9 in boys, without progressive breast/testicular enlargement) | Monitor closely; does not require treatment per se; check bone age and gonadotropins |
| True central precocious puberty (CPP) (progressive pubertal development with advanced bone age + pubertal LH response on GnRH stimulation) | GnRH analogue therapy (e.g., leuprorelin/leuprolide acetate depot injection monthly or 3-monthly) — suppresses gonadotropin secretion → halts pubertal progression → delays epiphyseal fusion → preserves growth potential |
| Combined GH + GnRH analogue | If CPP occurs while on GH therapy → add GnRH analogue to maximise GH benefit before epiphyseal closure |
| Parameter | Detail |
|---|---|
| Mechanism | Long-acting GnRH agonist → initial stimulation then desensitisation of pituitary GnRH receptors → ↓ LH/FSH → ↓ sex steroid production |
| Drug | Leuprorelin (leuprolide) depot — IM or SC injection |
| Dose | 3.75 mg IM monthly or 11.25 mg IM 3-monthly (paediatric formulations) |
| Monitoring | Tanner staging, growth velocity, bone age, LH/FSH levels (should be suppressed) |
| Duration | Continue until appropriate age for puberty (typically chronological age ~11 in girls, ~12 in boys) or when height target is acceptable |
| Side effects | Injection-site reactions, hot flushes, mood changes; long-term bone density monitoring if prolonged use |
| Problem | Management |
|---|---|
| Limb length discrepancy | Shoe lift (insole) for mild discrepancy ( < 2 cm); epiphysiodesis (surgical growth plate arrest of the longer leg) for more significant discrepancy approaching skeletal maturity |
| Scoliosis [1] | Regular spinal examination; physiotherapy; bracing if progressive; surgical correction rarely needed |
| Joint hypermobility | Physiotherapy, strengthening exercises |
| Domain | Intervention |
|---|---|
| Motor delay | Physiotherapy (hypotonia management, gross motor skills) |
| Speech and language delay (especially matUPD7 subtype) | Speech and language therapy — early referral |
| Learning support | Most RSS children have normal intelligence [1][2] but may need educational support for specific difficulties (attention, working memory) |
| Behavioural / emotional | Psychology referral if body image concerns, social difficulties, or anxiety related to short stature |
| Aspect | Detail |
|---|---|
| Recurrence risk | Most cases are sporadic (de novo epimutation or de novo UPD). Recurrence risk for parents is low ( < 1% for ICR1 LOM; slightly higher if structural rearrangement is found). MatUPD7 cases also have low recurrence risk |
| Prenatal diagnosis | Possible in subsequent pregnancies if the molecular mechanism is known, but rarely performed given low recurrence risk |
| Implications for the child | Phenotypic expression changes during childhood and adolescence with facial features and asymmetry usually becoming more subtle with age [2] — important to communicate to parents |
| Associated conditions to discuss | Hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma [2] — low risk but parents should be informed; screening abdominal USS may be offered, especially in 11p15 subtype |
This is a nuanced area. Unlike BWS where formal tumour screening protocols (3-monthly abdominal USS + serum AFP until age 7–8) are well-established, the tumour risk in RSS is much lower and less well-defined. Current practice:
| Recommendation | Detail |
|---|---|
| 11p15 LOM subtype | Consider periodic abdominal USS (e.g., 6–12 monthly) in early childhood — no formal consensus protocol exists, but shared pathogenetic locus with BWS warrants vigilance |
| matUPD7 subtype | No established tumour screening needed |
| Clinical awareness | Educate parents about warning signs: abdominal mass, abdominal pain, haematuria |
| Intervention | Detail |
|---|---|
| Parent education | Written information about RSS; connect with patient support groups (e.g., MAGIC Foundation, RSS/SGA Research & Education Fund, local HK rare disease support networks) |
| School liaison | Letter for school explaining the child's condition; arrange educational accommodations if needed |
| Transition planning | From paediatric to adult endocrinology; address fertility concerns (most RSS individuals have normal fertility, though males with cryptorchidism may have reduced spermatogenesis) |
| Mental health | Body image, bullying, social isolation related to short stature; proactive psychological support |
| Age Period | Priority Management Actions |
|---|---|
| Neonate | Glucose monitoring; frequent feeds; NGT if needed; dysmorphology assessment; molecular testing; genetic counselling |
| Infant (0–2 years) | Feeding support (dietitian, SLT); anti-reflux measures; hypoglycaemia prevention; developmental surveillance; growth plotting on RSS-specific chart |
| Toddler (2–4 years) | Initiate GH therapy if height ≤ –2.5 SDS with no catch-up [1]; continue nutritional optimisation; speech therapy if matUPD7; bone age assessment |
| Childhood (4–8 years) | Ongoing GH; monitor growth velocity and IGF-1; orthodontic assessment; scoliosis screening; learning support |
| Pre-puberty / Puberty (8–14 years) | Monitor for premature adrenarche / CPP; add GnRH analogue if CPP; limb length discrepancy management; psychological support; dental and orthopaedic review |
| Adolescence | GH continuation until near-final height; transition planning; fertility counselling; adult genetic follow-up |
High Yield Summary — Management of RSS
-
GH replacement is the mainstay growth treatment [1] — given under the SGA indication, NOT because the child is GH-deficient. Efficacy is modest [2].
-
GH dose for SGA = 35–70 mcg/kg/day SC, starting age 2–4 years, continuing until near-final height.
-
Hypoglycaemia prevention is the most critical acute management priority in neonates/infants — frequent feeds, avoid fasting, sick-day plan, IV dextrose for emergencies.
-
Premature adrenarche / CPP → GnRH analogue (leuprorelin) to delay epiphyseal fusion and preserve final height.
-
Associated neoplasms: hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma [2] — low risk but be vigilant; consider abdominal USS surveillance in 11p15 subtype.
-
Management is multidisciplinary and longitudinal: endocrinology, genetics, dietetics, SLT, orthopaedics, psychology, orthodontics.
-
Most cases are sporadic with low recurrence risk — genetic counselling should reassure parents.
-
RSS is a rare disease among common diseases [5] — few treatment options exist [1], reinforcing the importance of optimising available interventions.
Active Recall - Management of Silver-Russell Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 498–500, 510) — RSS clinical features, GH replacement, short stature approach, rare disease management [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 855–856) — RSS clinical manifestations, associated neoplasms, GH treatment ("modest efficacy") [5] GC lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 6) — Rare diseases among common diseases, Russell-Silver syndrome
Complications of Silver-Russell Syndrome
Complications in RSS arise from two broad mechanisms:
- Primary consequences of the underlying epigenetic defect — the imprinting disturbance directly causes growth restriction, metabolic dysregulation, and structural anomalies that in turn lead to complications.
- Secondary consequences of interventions — GH therapy, although beneficial, can itself produce complications that require monitoring.
Think of it as: the disease causes complications, and the treatment can cause complications. Both need surveillance.
I'll organise complications by system and by age since RSS is a lifelong condition where different complications dominate at different developmental stages.
Complications by System
1. Metabolic Complications
| Aspect | Detail |
|---|---|
| When | Neonatal period through infancy (highest risk); persists into early childhood but improves with age as body mass increases |
| Mechanism | Feeding difficulty (infancy) and hypoglycaemia [1]: (1) Extremely low glycogen stores due to small body size + reduced subcutaneous fat; (2) Relatively large brain (relative macrocephaly) → disproportionately high glucose demand; (3) Poor oral feeding (micrognathia, hypotonia) → inadequate caloric supply; (4) Reduced capacity for gluconeogenesis in the neonatal period |
| Consequences if untreated | Seizures, permanent neurological injury (hippocampal damage, cortical injury), developmental regression, death in extreme cases |
| Prevention | Frequent feeds, avoidance of fasting, sick-day plans, complex-carbohydrate snacks, emergency glucose protocols |
| Monitoring | Pre-feed glucose checks in neonates; bedside glucose during illness in older infants/toddlers |
Critical Point
Hypoglycaemia in RSS neonates/infants is recurrent and dangerous. Unlike transient neonatal hypoglycaemia in typical SGA infants (which resolves in 24–48 hours), RSS infants may have prolonged vulnerability lasting weeks to months due to persistent poor feeding, reduced fat mass, and high metabolic demand. This requires a structured prevention plan and parental education about sick-day rules.
| Aspect | Detail |
|---|---|
| When | Adolescence and adulthood |
| Mechanism | The "thrifty phenotype" hypothesis: a child programmed for undergrowth (↓ IGF-2, SGA) who then receives catch-up nutrition or GH therapy may develop disproportionate central adiposity relative to their lean limbs. SGA children have higher rates of insulin resistance, type 2 DM, dyslipidaemia, and cardiovascular disease in adulthood (Barker hypothesis / developmental origins of adult disease). GH therapy may exacerbate insulin resistance in the short term |
| Consequences | Impaired glucose tolerance, type 2 diabetes mellitus, dyslipidaemia, hypertension, increased cardiovascular risk in adulthood |
| Monitoring | Fasting glucose, HbA1c, lipid profile periodically during GH therapy and into adulthood; monitor BMI trajectory |
2. Growth and Endocrine Complications
| Aspect | Detail |
|---|---|
| Mechanism | IUGR and low birth weight, short stature < –2 SD [1]. Despite GH therapy (which has "modest efficacy"), final adult height remains below average (typically 148–155 cm male; 139–148 cm female without treatment; +5–8 cm with GH) |
| Psychosocial impact | Body image concerns, reduced self-esteem, bullying, social isolation, employment discrimination |
| Management | GH therapy (optimise timing and duration), GnRH analogue if early puberty, psychological support |
| Aspect | Detail |
|---|---|
| When | Pre-pubertal period (age 6–9 years) |
| Mechanism | Not fully understood — possibly related to altered adrenal sensitivity to ACTH, accelerated maturation of the hypothalamic-pituitary-gonadal axis, or catch-up growth triggering earlier pubertal activation. Body composition changes with GH therapy may also contribute |
| Consequence | Early puberty → early epiphyseal fusion → further compromise of already reduced final adult height. This is one of the most important preventable complications |
| Management | GnRH analogue therapy (leuprorelin) to suppress puberty and delay epiphyseal closure; continue GH concurrently |
| Complication | Mechanism | Risk in RSS Context |
|---|---|---|
| Worsening scoliosis | Accelerated asymmetric spinal growth during GH treatment | Higher risk in RSS due to pre-existing scoliosis [1] and body asymmetry |
| Slipped capital femoral epiphysis (SCFE) | Rapid growth → shear stress across the growth plate | Low absolute risk but must be suspected if hip/knee pain develops |
| Insulin resistance | GH is a counter-regulatory hormone → ↑ hepatic glucose output | Particularly concerning in RSS given pre-existing metabolic vulnerability (SGA) |
| Benign intracranial hypertension (pseudotumour cerebri) | Fluid retention → ↑ CSF pressure | Rare; present with headache, papilloedema |
| Progression of pre-existing neoplasms (theoretical) | GH/IGF-1 are growth factors | Low risk; screen before starting; ongoing clinical vigilance |
| Complication | Mechanism | Age Group | Management |
|---|---|---|---|
| Feeding difficulty [1] | Micrognathia → poor latch/suck mechanics; hypotonia [1] → reduced oromotor coordination; high palate → inefficient feeding | Neonate, infant | SLT feeding assessment, texture modification, NGT/gastrostomy if needed |
| Gastro-oesophageal reflux disease (GORD) | Small body habitus, oesophageal dysmotility, prolonged supine positioning | Infant, toddler | Positioning, thickened feeds, PPI (omeprazole), fundoplication in refractory cases |
| Constipation | Low dietary intake, low fibre, hypotonia of gut smooth muscle | Childhood | Dietary fibre, adequate hydration, osmotic laxatives if needed |
| Failure to thrive (FTT) | Cumulative effect of poor feeding + high metabolic demand + GORD + fasting intolerance | Infancy through early childhood | Caloric fortification, dietitian input, NGT, GH therapy improves appetite |
| Complication | Mechanism | Management |
|---|---|---|
| Body asymmetry (hemihypertrophy/hemihypotrophy) [1] | Mosaic epigenetic changes → differential growth of limbs/trunk. "May involve face/trunk/limb" [1] | Shoe lift for mild limb-length discrepancy; epiphysiodesis of the longer leg in significant cases; physiotherapy |
| Scoliosis [1] | Asymmetric vertebral growth + hypotonia + worsened by GH-accelerated growth | Regular spinal assessment; physiotherapy; bracing if progressive; surgical correction if severe |
| Joint hypermobility | Generalised connective tissue laxity | Physiotherapy, strengthening exercises |
| Dental crowding and malocclusion | Micrognathia [1] → small mandible cannot accommodate normal-sized teeth | Early orthodontic referral; may need serial extractions or orthognathic surgery in severe cases |
| Complication | Mechanism | Consequence | Management |
|---|---|---|---|
| Cryptorchidism [1] | Impaired testicular descent — likely related to growth gene dysregulation | Risk of infertility, testicular malignancy (seminoma) if undescended | Orchidopexy (surgical) — ideally by 6–12 months of age |
| Hypospadias [1] | Incomplete fusion of the urethral folds | Functional: abnormal urinary stream; cosmetic concerns | Surgical repair (hypospadias repair) — typically at 6–18 months |
| Posterior urethral valves (rare) | Structural GU anomaly | Obstructive uropathy → renal damage if undetected | Antenatal/postnatal USS; endoscopic valve ablation |
| Reduced fertility in males | Cryptorchidism + small body habitus | Oligospermia | Orchidopexy; fertility counselling in adolescence |
| Complication | Mechanism | Prognosis |
|---|---|---|
| Developmental delay [1] | Hypotonia + feeding difficulty + reduced opportunities for motor exploration due to small size + some intrinsic developmental delay | "But normal intelligence" [1] — most RSS children have IQ in the normal range |
| Speech and language delay | More common in matUPD7 subtype; possibly related to imprinted genes on chr 7 affecting brain development and oromotor function | Responds well to early speech therapy |
| Motor delay | Hypotonia → delayed sitting, crawling, walking | Physiotherapy; most achieve normal motor milestones with delay |
| Attention difficulties / learning differences | Minority of patients; mechanism unclear | Educational support; psychology input |
| Hypoglycaemic brain injury | If hypoglycaemia is severe/recurrent and inadequately treated | Potentially irreversible — emphasises importance of prevention |
Associated neoplasms: [2]
- Hepatoblastoma
- Hepatocellular carcinoma (HCC)
- Wilms tumour
- Testicular seminoma
- Craniopharyngioma
| Aspect | Detail |
|---|---|
| Mechanism | RSS involves 11p15.5 — the same locus implicated in BWS, which has a well-established tumour predisposition (especially Wilms tumour and hepatoblastoma). Although the epimutation in RSS is in the opposite direction to BWS, there remains a low but non-negligible risk of embryonal tumours, possibly due to incomplete epigenetic correction in some tissues or mosaic cell populations |
| Risk magnitude | Much lower than BWS ( < 5% in RSS vs ~7–10% in BWS). No formal screening protocol exists for RSS specifically |
| Tumour types | Embryonal tumours (hepatoblastoma, Wilms) — peak risk in early childhood (age 0–5 years); testicular seminoma — adolescence/young adulthood; craniopharyngioma — childhood/adolescence |
| Surveillance approach | Clinical awareness + parental education about warning signs (abdominal mass, haematuria, abdominal pain, precocious puberty from HCG-secreting tumours). Consider periodic abdominal USS in 11p15 subtype. Testicular examination in males with history of cryptorchidism |
BWS vs RSS — Tumour Risk Comparison
BWS (overgrowth, same locus): Well-established tumour screening protocol (3-monthly USS + AFP to age 7–8). RSS (undergrowth, same locus): No formal protocol, but clinical vigilance warranted — especially in the 11p15 LOM subtype which shares molecular features with BWS.
| Complication | Mechanism | Age Group |
|---|---|---|
| Reduced self-esteem | Persistent short stature + facial differences + body asymmetry → perceived difference from peers | School-age, adolescence |
| Bullying | Visible physical difference; small size makes child vulnerable | School-age |
| Body image disturbance | Asymmetry, facial features, short stature | Adolescence |
| Parental anxiety | Chronic condition with feeding difficulties, multiple hospital visits, growth concerns | All ages — affects the whole family |
| Social isolation | Physical limitations, self-consciousness | Adolescence |
Management: Proactive psychology referral, peer support groups, school education, and family-centred counselling. Building self-efficacy through strengths-based approaches.
| Age | Key Complications |
|---|---|
| Neonate | Hypoglycaemia, feeding failure, hypothermia (low fat stores) |
| Infant | Persistent hypoglycaemia, GORD, FTT, developmental delay |
| Early childhood | Short stature, dental crowding, speech delay, tumour risk (hepatoblastoma, Wilms) |
| Late childhood / pre-puberty | Premature adrenarche, scoliosis progression (especially on GH), limb-length discrepancy becoming functionally significant |
| Puberty | Central precocious puberty → compromised final height, body image concerns |
| Adolescence / Young adulthood | Persistent short stature, metabolic syndrome risk, fertility issues (males with cryptorchidism), psychological impact, testicular seminoma risk |
High Yield Summary — Complications of RSS
-
Hypoglycaemia = most dangerous acute complication (neonates/infants). Can cause seizures and brain injury if not prevented.
-
Persistent short stature = most significant chronic complication. GH therapy helps but efficacy is modest [2]. Final height remains below average.
-
Premature adrenarche / central precocious puberty → early epiphyseal fusion → further height compromise. Treat with GnRH analogue.
-
Scoliosis [1] may be worsened by GH therapy — regular monitoring required.
-
Associated neoplasms: hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma [2] — low risk but requires clinical vigilance; shared locus with BWS explains the overlap.
-
GU anomalies (cryptorchidism, hypospadias) [1] → fertility implications; early surgical correction.
-
Metabolic syndrome in adulthood — the "Barker hypothesis": SGA children with catch-up growth have increased cardiovascular risk. Monitor glucose, lipids, BP longitudinally.
-
Psychosocial complications are often under-recognised — proactive psychological support and family-centred care are essential throughout.
-
Developmental delay occurs but intelligence is usually normal [1] — reassure parents while providing appropriate developmental support.
Active Recall - Complications of Silver-Russell Syndrome
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 65, 500) — RSS clinical features (feeding difficulty, hypoglycaemia, body asymmetry, scoliosis, GU anomalies, developmental delay with normal intelligence, short stature) [2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 855–856) — RSS associated neoplasms (hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma), GH modest efficacy [3] GC lecture slides: CFB (PAE02) Child growth and development.pdf (pp. 33–34) — Dysmorphism with a recognizable syndrome, Russell-Silver syndrome [5] GC lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 6) — Rare diseases among common diseases, Russell-Silver syndrome
High Yield Summary
-
RSS is the most common genetic cause of IUGR — always consider it in an SGA baby who fails to catch up.
-
Molecular basis: ~40–50% have ICR1 hypomethylation at 11p15.5 (↓ IGF-2); ~5–10% have matUPD7; ~40% remain molecularly unconfirmed.
-
RSS and BWS are mirror syndromes: Same locus (11p15.5), opposite epimutations. RSS = undergrowth, BWS = overgrowth.
-
PICNICS mnemonic for pathological short stature — RSS falls under "I" (IUGR as part of a syndrome).
-
Classic clinical features: Triangular face (broad forehead + micrognathia), relative macrocephaly, body asymmetry, clinodactyly of 5th finger, feeding difficulty, hypoglycaemia.
-
Relative macrocephaly means the head circumference is NORMAL but appears large because the body is disproportionately small.
-
GH replacement is the mainstay of growth treatment.
-
Hypoglycaemia is a dangerous early complication — monitor and manage aggressively.
-
Premature adrenarche may compromise final height → consider GnRH analogue if true precocious puberty develops.
-
Facial features and asymmetry become more subtle with age — diagnosis is easier in early childhood.
High Yield Summary — Diagnosis of RSS
-
NH-CSS is the clinical diagnostic tool: ≥ 4/6 criteria = clinical RSS → molecular testing.
-
First-line molecular test = MS-MLPA at 11p15.5 (detects ICR1 hypomethylation + copy number changes). If negative → matUPD7 testing.
-
~60% of clinically diagnosed RSS have a confirmable molecular cause [1]; ~40% remain molecularly unconfirmed but the clinical diagnosis still stands.
-
Standard karyotype will be NORMAL in RSS — you need methylation-specific testing. Do not rely on karyotype or CMA alone.
-
GH stimulation test is performed to classify the GH treatment indication (SGA vs GHD) — most RSS children are not GH-deficient.
-
Bone age is typically delayed → good prognostic sign for growth potential.
-
Always plot on growth chart, compare with weight centile and mid-parental centile [1] — this is the fundamental first step for any child with short stature.
-
RSS is a rare disease — challenging to diagnose due to relative rarity, age-dependent findings, sporadic occurrence, and biological variability/penetrance [1].
High Yield Summary — Management of RSS
-
GH replacement is the mainstay growth treatment [1] — given under the SGA indication, NOT because the child is GH-deficient. Efficacy is modest [2].
-
GH dose for SGA = 35–70 mcg/kg/day SC, starting age 2–4 years, continuing until near-final height.
-
Hypoglycaemia prevention is the most critical acute management priority in neonates/infants — frequent feeds, avoid fasting, sick-day plan, IV dextrose for emergencies.
-
Premature adrenarche / CPP → GnRH analogue (leuprorelin) to delay epiphyseal fusion and preserve final height.
-
Associated neoplasms: hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma [2] — low risk but be vigilant; consider abdominal USS surveillance in 11p15 subtype.
-
Management is multidisciplinary and longitudinal: endocrinology, genetics, dietetics, SLT, orthopaedics, psychology, orthodontics.
-
Most cases are sporadic with low recurrence risk — genetic counselling should reassure parents.
-
RSS is a rare disease among common diseases [5] — few treatment options exist [1], reinforcing the importance of optimising available interventions.
High Yield Summary — Complications of RSS
-
Hypoglycaemia = most dangerous acute complication (neonates/infants). Can cause seizures and brain injury if not prevented.
-
Persistent short stature = most significant chronic complication. GH therapy helps but efficacy is modest [2]. Final height remains below average.
-
Premature adrenarche / central precocious puberty → early epiphyseal fusion → further height compromise. Treat with GnRH analogue.
-
Scoliosis [1] may be worsened by GH therapy — regular monitoring required.
-
Associated neoplasms: hepatoblastoma, HCC, Wilms tumour, testicular seminoma, craniopharyngioma [2] — low risk but requires clinical vigilance; shared locus with BWS explains the overlap.
-
GU anomalies (cryptorchidism, hypospadias) [1] → fertility implications; early surgical correction.
-
Metabolic syndrome in adulthood — the "Barker hypothesis": SGA children with catch-up growth have increased cardiovascular risk. Monitor glucose, lipids, BP longitudinally.
-
Psychosocial complications are often under-recognised — proactive psychological support and family-centred care are essential throughout.
-
Developmental delay occurs but intelligence is usually normal [1] — reassure parents while providing appropriate developmental support.
Beckwith-wiedemann Syndrome
Beckwith-Wiedemann syndrome is a congenital overgrowth disorder, typically presenting at birth or in early childhood, characterized by macrosomia, macroglossia, omphalocele, visceromegaly, and an increased risk of embryonal tumors such as Wilms tumor and hepatoblastoma.
Patau Syndrome (trisomy 13)
Patau syndrome is a severe chromosomal disorder caused by an extra copy of chromosome 13, presenting at birth with holoprosencephaly, cleft lip/palate, polydactyly, and major cardiac defects, with most affected infants dying within the first year of life.